BSE Pharma Sector Regulatory Filings — April 01, 2026

Completed acquisition of 100% VISUfarma B.V. and subsidiaries effective April 01, 2026, satisfying all closing conditions per prior intimations, unlocking immediate European expansion

Nanomi B.V. acquiring 43.38% (11,794,497 shares) in MPPI for USD 39.6M at arm's-length EY valuation, boosting ownership to 100% and consolidating Philippines pharma distribution

MPPI operates in high-growth Philippines pharma trading/importing, with prior FY24 turnover +34.8% YoY signaling rebound potential despite FY25 dip

No promoter/promoter group interest in MPPI deal, approved by Audit Committee, indicating clean governance and management conviction in strategic fit

VISUfarma deal complies with Reg 30 SEBI Listing Obligations, with detailed disclosures since Sep 2025, reducing disclosure risks and enhancing transparency

MPPI FY25 turnover decline of 10.8% YoY to PHP 2,096.6M after exceptional +34.8% prior year, potentially flagging normalization rather than structural weakness

Full 100% ownership in MPPI post-deal strengthens competitive positioning in Philippines medical devices/pharma, a key emerging market

Sequential M&A momentum (VISUfarma closed, MPPI pending) vs stagnant peers in BSE PHARMA signals superior capital deployment for growth

No governmental approvals needed for MPPI acquisition, accelerating timeline to end-May 2026 vs typical regulatory delays

MPPI revenue down 10.8% YoY in FY25 (PHP 2,096.6M vs PHP 2,351.2M FY24), decelerating from +34.8% growth, indicating target underperformance

Mixed sentiment on MPPI deal due to target's YoY revenue contraction, contrasting positive VISUfarma closure

FY25 turnover declined 10.8% YoY to PHP 2,096.6M from PHP 2,351.2M FY24, after +34.8% prior growth, signaling potential demand slowdown or competition

Post-VISUfarma closure (Apr 01, 2026), execution risks in merging Netherlands ops with Lupin, including cultural/currency mismatches

USD 39.6M for 43.38% stake amid target's revenue decline raises overpayment risk despite EY valuation

Heavy Philippines exposure via MPPI (100% post-deal) vulnerable to PHP volatility and local regulatory shifts in pharma imports

MPPI growth reversal from +34.8% FY24 to -10.8% FY25 YoY could indicate cyclical downturn, pressuring Lupin consolidated metrics

Reliance on prior filings (Sep/Dec 2025, Feb 2026) for VISUfarma details may hide evolving risks not updated in latest intimation

Mixed outlook on MPPI acquisition (declining target revenues) vs positive VISUfarma, creating uncertainty in M&A pipeline

USD 39.6M outlay for minority stake without disclosed funding details, potential strain if no fresh capital allocation updates

Immediate 100% control of Netherlands ophthalmics firm post-Apr 01, 2026 closure offers Europe entry synergies and revenue add-on

USD 39.6M for 43.38% stake to reach 100% by end-May 2026 enables full consolidation of PHP 2B+ turnover Philippines platform

MPPI's market position in pharma/devices trading undervalued post -10.8% YoY dip, with FY24 +34.8% precedent for rebound under Lupin

Arm's-length pricing for MPPI at certified valuation positions deal as accretive vs potentially higher market multiples

Back-to-back deals (VISUfarma closed, MPPI pending) highlight acquisition expertise, potential for more tuck-ins in BSE PHARMA

MPPI deal requires no regulatory nods, fast-tracking synergies vs peers facing delays, alpha from execution speed

MPPI revenue normalization (-10.8% YoY FY25) after boom year offers cost optimization and growth levers under full Lupin control

Lupin's dual M&A (Europe/Asia) vs quiet BSE PHARMA peers creates relative growth alpha through inorganic acceleration

Lupin completes 1st VISUfarma acquisition and advances 2nd MPPI minority buyout (both materiality 8/10), signaling BSE PHARMA tuck-in trend for full control [Implication: Favor active acquirers for market share gains]

Lupin targets Europe (Netherlands VISUfarma) and Asia (Philippines MPPI 100% stake), contrasting domestic focus in sector [Implication: Hedge India risks via EM/EU exposure]

MPPI exemplifies post-boom slowdown (-10.8% YoY FY25 after +34.8% FY24), potential sector pattern in cyclical pharma distribution [Implication: Watch for normalization in high-growth targets]

Both Lupin deals arm's-length (EY val for MPPI), no approvals/promoter conflicts, above sector avg governance in filings [Implication: Reduced regulatory overhang boosts execution probability]

Positive on completed VISUfarma vs mixed MPPI (revenue dip), highlighting BSE PHARMA M&A bifurcation by target health [Implication: Prioritize positive sentiment deals for near-term upside]

Monitor end-May 2026 completion of USD 39.6M minority buyout for any delays or revised terms post-FY25 revenue decline

Track Q2 2026 updates on Netherlands ops synergies post-Apr 01 closure, including initial revenue/contribution metrics

Watch FY26 Philippines turnover recovery from -10.8% YoY FY25 base, potential catalysts in next quarterly filing

Upcoming earnings for impact of VISUfarma on revenue growth and MPPI on geographic mix (no date specified)

Insider activity or new intimations post-dual deals, gauging management conviction in further BSE PHARMA consolidation

PHP/USD fluctuations affecting MPPI's PHP 2,096.6M FY25 turnover value in Lupin books, monitor forex updates

Any Reg 30 follow-ups on VISUfarma (prior Sep 2025 details) or MPPI Audit Committee outcomes for hidden risks